Mylan Asks PTAB To Reconsider Denial Of Viread Reviews
Saying the Patent Trial and Appeal Board's decisions not to review patents related to Gilead Sciences Inc.'s HIV and hepatitis drug Viread represented an "extreme departure" from settled law on obviousness,...To view the full article, register now.
Already a subscriber? Click here to view full article